TTX-080 is under clinical development by Tizona Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTX-080’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTX-080 overview
TTX-080 is under development for the treatment of metastatic solid tumors including head and neck squamous cell carcinoma, acral melanoma, non-small cell lung cancer, metastatic colorectal cancer, renal cell carcinoma (RCC), HER2 negative breast cancer and triple negative breast cancer. The drug candidate is a monoclonal antibody developed based on OmniAb technology. The drug candidate acts by targeting HLA-G.
Tizona Therapeutics overview
Tizona Therapeutics is an immunology company which develops treatments for cancer and autoimmune disorders. Its lead product candidate anti-CD39 antibody inhibits the breakdown of excessive ATP released from dying tumor cells to immune suppressive adenosine leading to immune activation. Tizona’s immunotherapies are designed to modulate the activity of immunosuppressive cells including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tolerogenic dendritic cells (DCs) that activate the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases.The company is backed by MPM Capital Inc, Abingworth LLP, Amgen Inc, Astellas Venture Management LLC, and LSV Capital Management LLC. Tizona Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of TTX-080’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - TTX-080 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Premium Insights
The gold standard of business intelligence.
